In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharmaceutical Trends In 2012: Regulatory And Market Strides Paper Over Existential Dilemmas

Executive Summary

The biopharma industry enjoyed regulatory success in 2012 that was recognized by investors. The stench from the carcasses of industry’s genericized blockbusters has begun to fade, but R&D productivity for the most part remains poor, expensive late-stage failures abound, and industry is still searching for sustainable business models.

You may also be interested in...



Lilly Back In The BACE Space Following Deal With AstraZeneca

Eli Lilly has signed on as a risk-sharing partner with AstraZeneca to develop a BACE inhibitor for Alzheimer’s disease. The deal gives Lilly a mid-stage asset in the challenging field after two of its own candidates failed in late-stage trials.

Biopharma IPOs Start To Gear Up For 2013 After A Lull

Biopharma and diagnostic IPOs have been relatively quiet since before the U.S. presidential election, but companies are again starting on road shows and updating prospectuses in anticipation of recaptured momentum.

FDA’s Very Big Year: Drug Approvals Approach Record Levels

In 2012, FDA new drug approvals reached levels not seen since the peak years of the 1990s. FDA counts 39 NMEs; The RPM Report tracks a different metric—ICTs—and FDA topped 30 for the first time since 1999. The approval spike clearly reflects a regulatory agency operating at peak efficiency. Is there also (at last) a true bulge in innovative products making it through development?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel